Vectura Group (LON:VEC) Price Target Cut to GBX 88

Vectura Group (LON:VEC) had its price objective lowered by equities researchers at Royal Bank of Canada from GBX 92 ($1.20) to GBX 88 ($1.15) in a note issued to investors on Wednesday, September 12th. The brokerage currently has a “sector performer” rating on the stock. Royal Bank of Canada’s price objective would indicate a potential upside of 14.96% from the stock’s current price.

Several other equities analysts have also weighed in on VEC. Peel Hunt reissued a “hold” rating on shares of Vectura Group in a research note on Thursday, May 17th. Shore Capital cut their target price on Vectura Group from GBX 105 ($1.37) to GBX 78 ($1.02) and set a “hold” rating on the stock in a research note on Monday, July 16th. Numis Securities reissued a “buy” rating on shares of Vectura Group in a research note on Wednesday, September 12th. Finally, JPMorgan Chase & Co. reissued an “overweight” rating on shares of Vectura Group in a research note on Wednesday, September 12th. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Vectura Group has a consensus rating of “Buy” and an average price target of GBX 127.67 ($1.67).

LON:VEC traded up GBX 1.25 ($0.02) during mid-day trading on Wednesday, hitting GBX 76.55 ($1.00). The company had a trading volume of 666,890 shares, compared to its average volume of 4,610,000. Vectura Group has a fifty-two week low of GBX 70 ($0.91) and a fifty-two week high of GBX 166.97 ($2.18).

Vectura Group Company Profile

Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta and Anoro Ellipta for the treatment of COPD.

Further Reading: Leveraged Buyout (LBO) Explained

Analyst Recommendations for Vectura Group (LON:VEC)

Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply